Antipsychotic-induced Tardive dyskinesia: from biological basis to clinical management

H Salem, T Pigott, XY Zhang, CP Zeni… - Expert Review of …, 2017 - Taylor & Francis
H Salem, T Pigott, XY Zhang, CP Zeni, AL Teixeira
Expert Review of Neurotherapeutics, 2017Taylor & Francis
Introduction: Tardive dyskinesia (TD) is a chronic and disabling movement disorder with a
complex pathophysiological basis. A significant percentage of patients does not receive
correct diagnosis, resulting in delayed or inaccurate treatment and poor outcome. Therefore,
there is a critical need for prompt recognition, implementation of efficacious treatment
regimens and long-term follow up of patients with TD. Areas covered: The current paper
provides an overview of emerging data concerning proposed pathophysiology theories …
Abstract
Introduction: Tardive dyskinesia (TD) is a chronic and disabling movement disorder with a complex pathophysiological basis. A significant percentage of patients does not receive correct diagnosis, resulting in delayed or inaccurate treatment and poor outcome. Therefore, there is a critical need for prompt recognition, implementation of efficacious treatment regimens and long-term follow up of patients with TD.
Areas covered: The current paper provides an overview of emerging data concerning proposed pathophysiology theories, epidemiology, risk factors, and therapeutic strategies for TD.
Expert commentary: Despite considerable research efforts, TD remains a challenge in the treatment of psychosis as the available strategies remain sub-optimal. The best scenario will always be the prophylaxis or prevention of TD, which entails limiting the use of antipsychotics.
Taylor & Francis Online